David Ricks, Eli Lilly CEO (Paulo Nunes dos Santos/Bloomberg via Getty Images)
October 10, 2024 03:31 PM EDTUpdated 07:03 PM
Startups
Deals

Eli Lil­ly inks an­oth­er obe­si­ty pact, dou­bling down on small Swiss part­ner

Kyle LaHucik

Senior Reporter

Eli Lil­ly is re­turn­ing to Key­Bio­science, a nim­ble Swiss biotech, sev­en years af­ter orig­i­nal­ly link­ing arms with the start­up to work on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times